Patients with active bleeding complications who concomitantly develop overt pulmonary embolism (PE) present distinct therapeutic dilemmas, since they are perceived to be at substantial risk for the progression of the embolism in the absence of treatment and for aggravation of the hemorrhagic lesions if treated with anticoagulants. A 76-year-old patient with nephrotic syndrome, which is associated with an increased risk of thromboembolism, concurrently developed acute PE and intracranial bleeding because of traumatic brain injury. In this case, we prioritized the treatment for PE with the intravenous unfractionated heparin followed by warfarinization. Despite the transient hemorrhagic progression of the brain contusion after the institution ...
Background. Physicians treating acute pulmonary embolism (PE) are faced with difficult management de...
Pulmonary embolism is a common condition with a high mortality. We describe a previously healthy 68-...
Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare systems. Guideli...
Decision-making is a complex issue especially in severe multi-pathological patients, whose processe...
Abstract Background Anticoagulation is the mainstay of treatment for pulmonary embolism. However, if...
Introduction: In patients with known malignancy and possible intracranial metastatic disease who are...
Pulmonary embolism (PE) is caused by emboli, which have originated from venous thrombi, travelling t...
Przedstawiono opisy 2 chorych, którzy po krwawieniu do ośrodkowego układu nerwowego doznali zatorowo...
The clinical presentation of pulmonary embolism (PE) varies widely, ranging from only limited sympto...
While systemic intravenous thrombolysis decreases mortality in patients with high-risk pulmonary emb...
Pulmonary embolism can be a catastrophic event that can result in early death or serious hemodynamic...
Catheter-directed thrombolysis (CDT) for the treatment of acute pulmonary embolism (PE) has gained p...
Introduction. Diagnostic and therapeutic algorithms for pulmonary embolism (PE) have been frequently...
Patients with hypercoagulable conditions, including malig-nancy, are at increased risk of recurrent ...
Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare systems. Guideli...
Background. Physicians treating acute pulmonary embolism (PE) are faced with difficult management de...
Pulmonary embolism is a common condition with a high mortality. We describe a previously healthy 68-...
Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare systems. Guideli...
Decision-making is a complex issue especially in severe multi-pathological patients, whose processe...
Abstract Background Anticoagulation is the mainstay of treatment for pulmonary embolism. However, if...
Introduction: In patients with known malignancy and possible intracranial metastatic disease who are...
Pulmonary embolism (PE) is caused by emboli, which have originated from venous thrombi, travelling t...
Przedstawiono opisy 2 chorych, którzy po krwawieniu do ośrodkowego układu nerwowego doznali zatorowo...
The clinical presentation of pulmonary embolism (PE) varies widely, ranging from only limited sympto...
While systemic intravenous thrombolysis decreases mortality in patients with high-risk pulmonary emb...
Pulmonary embolism can be a catastrophic event that can result in early death or serious hemodynamic...
Catheter-directed thrombolysis (CDT) for the treatment of acute pulmonary embolism (PE) has gained p...
Introduction. Diagnostic and therapeutic algorithms for pulmonary embolism (PE) have been frequently...
Patients with hypercoagulable conditions, including malig-nancy, are at increased risk of recurrent ...
Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare systems. Guideli...
Background. Physicians treating acute pulmonary embolism (PE) are faced with difficult management de...
Pulmonary embolism is a common condition with a high mortality. We describe a previously healthy 68-...
Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare systems. Guideli...